210 related articles for article (PubMed ID: 18344641)
1. Recurrent gefitinib-induced interstitial lung disease.
Suzuki M; Asahina H; Konishi J; Yamazaki K; Nishimura M
Intern Med; 2008; 47(6):533-6. PubMed ID: 18344641
[TBL] [Abstract][Full Text] [Related]
2. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
Beom SH; Kim DW; Sim SH; Keam B; Park JH; Lee JO; Kim TM; Lee SH; Heo DS
Cancer Res Treat; 2016 Jan; 48(1):88-97. PubMed ID: 25761482
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers.
Kitajima H; Takahashi H; Harada K; Kanai A; Inomata S; Taniguchi H; Saikai T; Abe S
Respirology; 2006 Mar; 11(2):217-20. PubMed ID: 16548909
[TBL] [Abstract][Full Text] [Related]
5. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
Endo M; Johkoh T; Kimura K; Yamamoto N
Lung Cancer; 2006 May; 52(2):135-40. PubMed ID: 16574271
[TBL] [Abstract][Full Text] [Related]
6. Interstitial lung disease associated with gefitinib.
Kataoka K; Taniguchi H; Hasegawa Y; Kondoh Y; Kimura T; Nishiyama O; Imaizumi K; Kawabe T; Kume H; Shimokata K
Respir Med; 2006 Apr; 100(4):698-704. PubMed ID: 16137874
[TBL] [Abstract][Full Text] [Related]
7. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Chang SC; Chang CY; Chang SJ; Yuan MK; Lai YC; Liu YC; Chen CY; Kuo LC; Yu CJ
Clin Lung Cancer; 2013 Jan; 14(1):55-61. PubMed ID: 22607779
[TBL] [Abstract][Full Text] [Related]
9. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.
Aoe K; Hiraki A; Murakami T; Maeda T; Umemori Y; Katayama H; Eda R; Takeyama H
Anticancer Res; 2005; 25(1B):415-8. PubMed ID: 15816604
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
[TBL] [Abstract][Full Text] [Related]
11. Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Wang KF; Chang CY; Chang SC; Liu YC; Yuan MK; Yang YH
J Chin Med Assoc; 2013 Mar; 76(3):173-5. PubMed ID: 23497972
[TBL] [Abstract][Full Text] [Related]
12. Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer.
Shih YN; Chiu CH; Tsai CM; Perng RP
J Chin Med Assoc; 2005 Apr; 68(4):183-6. PubMed ID: 15850069
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.
Tsuboi M; Kato H; Nagai K; Tsuchiya R; Wada H; Tada H; Ichinose Y; Fukuoka M; Jiang H
Anticancer Drugs; 2005 Nov; 16(10):1123-8. PubMed ID: 16222155
[TBL] [Abstract][Full Text] [Related]
15. [Four cases of interstitial lung disease induced by erlotinib and a review of the literatures].
Wu X; Gao G; Ren S; Zhou C
Zhongguo Fei Ai Za Zhi; 2012 Aug; 15(8):494-8. PubMed ID: 22901999
[TBL] [Abstract][Full Text] [Related]
16. Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease.
Yuan MK; Chang CY; Chang SC; Chang SJ; Tang GJ; Wei YF; Liu YC; Chen CY; Yu CJ
Int J Clin Pharmacol Ther; 2011 Oct; 49(10):587-93. PubMed ID: 21961483
[TBL] [Abstract][Full Text] [Related]
17. Interstitial lung disease and gefitinib.
Murashige N; Tanimoto T; Oshima Y
N Engl J Med; 2010 Oct; 363(16):1578-9; author reply 1579-80. PubMed ID: 20942679
[No Abstract] [Full Text] [Related]
18. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
Akamatsu H; Inoue A; Mitsudomi T; Kobayashi K; Nakagawa K; Mori K; Nukiwa T; Nakanishi Y; Yamamoto N
Jpn J Clin Oncol; 2013 Jun; 43(6):664-8. PubMed ID: 23585689
[TBL] [Abstract][Full Text] [Related]
19. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Kudoh S; Kato H; Nishiwaki Y; Fukuoka M; Nakata K; Ichinose Y; Tsuboi M; Yokota S; Nakagawa K; Suga M; ; Jiang H; Itoh Y; Armour A; Watkins C; Higenbottam T; Nyberg F
Am J Respir Crit Care Med; 2008 Jun; 177(12):1348-57. PubMed ID: 18337594
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Yokoyama Y; Sonobe M; Yamada T; Sato M; Menju T; Aoyama A; Sato T; Chen F; Omasa M; Date H
Int J Clin Oncol; 2015 Dec; 20(6):1122-9. PubMed ID: 25953679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
